A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma

This study is comparing two treatment combinations for elderly patients newly diagnosed with multiple myeloma (a blood cancer) who cannot have a stem cell transplant: DRd (daratumumab, lenalidomide, dexamethasone) versus VRd-lite (bortezomib, lenalidomide, dexamethasone at lower doses). **You may be eligible if...** - You are 65 or older and newly diagnosed with multiple myeloma - Your diagnosis meets standard criteria, including measurable disease in blood or urine tests, or abnormal plasma cells in bone marrow - You have not received prior treatment for multiple myeloma - Your organ function (kidney, liver, blood counts) is adequate **You may NOT be eligible if...** - You have already received treatment for multiple myeloma - You have had a stem cell transplant - You have serious heart, kidney, or other organ problems that prevent treatment - You are pregnant or unable to use contraception Talk to your doctor to see if this trial is right for you.